



## New Insights in Gastric, Colorectal, and Pancreatic Cancer

Guest Editor:

**Dr. John K. Triantafillidis**

Director IBD Unit, Metropolitan  
General Hospital, 15562  
Hologos, Greece

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editor

Gastric, colorectal and pancreatic cancer represent the most important malignant neoplasms of the digestive system in terms of frequency and clinical importance. Advances in conservative treatment are especially impressive. For example, immunotherapy of these cancers alone or in combination with systemic chemotherapy is the therapeutic strategy of the present and the future.

This Special Issue focuses on the recent data regarding these three neoplasms, intending to cover among others, the following topics:

- Mechanisms of carcinogenesis;
- Tumor cell biology;
- Hereditary gastric, CRC and pancreatic cancer;
- Polyps (gastric and colorectal);
- Biomarkers (diagnostic and prognostic);
- Tumor staging;
- Imaging techniques;
- Animal models;
- Stem cells;
- Advances in chemotherapy;
- Immunotherapy in gastric and pancreatic cancer, alone or in combination;
- Advances in the treatment of metastatic pancreatic, CRC and gastric cancer.



We aspire for this Special Issue to cover at least part of the wide spectrum of the etiologies, diagnoses and treatments of these neoplasms, always in the light of a multidisciplinary approach.



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)